Pharma companies and healthcare stakeholders should closely monitor these conversations as leading indicators for potential regulatory and market shifts
Not recommended for children
Consider tirzepatide weight loss as a viable option for achieving sustainable weight management
Szsz AM, Lnczky A, Nagy , Frster S, Hark K, Green JE, et al
At 208 weeks, semaglutide was associated with mean reduction in weight (10.2%), waist circumference (7.7 cm) and waist-to-height ratio (6.9%) versus placebo (1.5%, 1.3 cm and 1.0%, respectively
Meanwhile, the expression of hypertrophic marker, such as ANP and MYH7, were enhanced under pressure overload